PATENT CLAIM ANALYSIS

Application Number: 16038739
Application Type: Utility
Filing Date: 2018-07
Publication Date: 2018-11
Patent Classification: ["514", "093000"]

Abstract:
The present invention provides compounds of Formula (I): or stereoisomers, tautomers, pharmaceutically acceptable salts, solvates or prodrugs thereof, wherein all the variables are as defined herein. These compounds are selective LPA receptor inhibitors.

Claim (Index 43):
The method of  claim 32 , wherein the stereoisomer is an enantiomer or a diastereomer.

Metadata:
- Claim Count in Document: 35.0
- Percentile: 95.0
- Lexical Diversity: 1.2
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['15628104', '15323967', '15534105', '14352554', '14488294']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7330283103400193
- 35 USC 102 Novelty (BERT): 0.5533994079202319
- Combined Prediction Score: 0.7150654200980405
- Mean Citation Score: 310.378278
- Max Citation Score: 437.55276
- Similarity Product: 235.3615990120411

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 0
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test